Compare Accenture plc (ACN) vs Zoetis Inc (ZTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs Zoetis Inc — how do they compare? Accenture plc trades at $137.69 (market cap $86.98B), while Zoetis Inc trades at $75.18 (market cap $31.62B). The key difference: Accenture plc is far larger — about 2.8× Zoetis Inc's market cap, and Accenture plc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ACN | ZTS | |
|---|---|---|
Market Cap | $86.98B | $31.62B |
Sector | Technology | Health |
52-Week High | $303.33 | $158.80 |
52-Week Low | $124.41 | $71.91 |
Enterprise Value | $85.20B | $38.92B |
Dividend Yield | 4.59% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $137.19, up 0.17% on the day, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 11.35, net income margin of 10.66%, and consistent earnings beats in recent quarters. Recent news highlights strategic AI partnerships with TEPCO Solution Advance and AlphaSense, reinforcing its focus on digital transformation services. Operating cash flow strengthened to $11.47 billion in 2025, supporting dividend payments and growth initiatives.
The outlook for ACN is positive, driven by strong analyst sentiment with a consensus price target of $193.92 and 66% buy ratings. Key opportunities include revenue growth from AI adoption and global consulting demand. Risks involve competitive pressures, macroeconomic sensitivity, and execution challenges in integrating new technologies. The stock offers value with reasonable valuation multiples and a track record of profitability.
Zoetis (ZTS) trades at $76.29, up 1.99% on the day, with a bearish technical signal from moving averages. The company maintains strong profitability with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty despite a consensus analyst price target of $101.43.
The stock presents a valuation opportunity with a P/E of 12.36 below industry averages, but faces near-term headwinds from legal challenges and mixed earnings performance. Upside potential exists if the company can overcome litigation concerns and return to consistent earnings beats, while downside risk persists from ongoing legal proceedings and competitive pressures in the animal health market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
